Enhanced and persistent levels of interleukin (IL)-17+CD4+ T cells and serum IL-17 in patients with early inflammatory arthritis

Clinical and Experimental Immunology

Volumn 174, Issue 2, 2013, Pages 292-301

  Gullick, N J ^a,b   Abozaid, H S ^a,d   Jayaraj, D M ^a,b   Evans, H G ^a,b   Scott, D L ^a,b   Choy, E H ^c   Taams, L S ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^d Sohag University   (Egypt)

Author keywords

Early arthritis; IL 17; Monocyte; Th17; Treatment response

Indexed keywords

ALPHA INTERFERON; CHEMOKINE; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; IONOMYCIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PHORBOL 13 ACETATE 12 MYRISTATE; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE ACTIVITY; EARLY INFLAMMATORY ARTHRITIS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNITY; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; TH17 CELL;

EARLY ARTHRITIS; IL-17; MONOCYTE; TH17; TREATMENT RESPONSE;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CHEMOKINE CCL3; CROSS-SECTIONAL STUDIES; CYTOKINES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-17; MALE; MIDDLE AGED; TH17 CELLS; TREATMENT OUTCOME;

EID: 84885168589     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12167     Document Type: Article

References (43)

1. Hazes JMW, Luime JJ. The epidemiology of early inflammatory arthritis. Nat Rev Rheumatol 2011; 7:381-390.
2. Raza K, Falciani F, Curnow SJ etal. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther 2005; 7:R784-795.
3. Leipe J, Grunke M, Dechant C etal. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 2010; 62:2876-2885.
4. Lubberts E, Joosten LA, Oppers B etal. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol 2001; 167:1004-1013.
5. Lubberts E, Koenders MI, Oppers-Walgreen B etal. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004; 50:650-659.
6. Miossec P. Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy. Arthritis Rheum 2003; 48:594-601.
7. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009; 361:888-898.
8. Koenders MI, Lubberts E, van de Loo FAJ etal. Interleukin-17 acts independently of TNF-alpha under arthritic conditions. J Immunol 2006; 176:6262-6269.
9. Bush KA, Farmer KM, Walker JS, Kirkham BW. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum 2002; 46:802-805.
10. Genovese MC, Van den Bosch F, Roberson SA etal. LY2439821, a humanized anti-IL-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase 1 randomized, double-blind, placebo-controlled, proof of concept study. Arthritis Rheum 2010; 62:929-939.
11. Hueber W, Patel DD, Dryja T etal. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010; 2:52ra72.
12. Stamp LK, Easson A, Petterson L, Highton J, Hessian PA. Monocyte derived interleukin (IL)-23 is an important determinant of synovial IL-17A expression in rheumatoid arthritis. J Rheumatol 2009; 36:2403-2408.
13. Kirkham BW, Lassere MN, Edmonds JP etal. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 2006; 54:1122-1131.
14. Gullick NJ, Evans HG, Church LD etal. Linking power doppler ultrasound to the presence of Th17 cells in the rheumatoid arthritis joint. PLoS ONE 2010; 5:e12516.
15. Arnett FC, Edworthy SM, Bloch DA etal. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-324.
16. Edmonds J, Saudan A, Lassere M, Scott D. Introduction to reading radiographs by the Scott modification of the Larsen method. J Rheumatol 1999; 26:740-742.
17. Aletaha D, Neogi T, Silman AJ etal. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010; 69:1580-1588.
18. Metawi S, Abbas D, Kamal M, Ibrahim M. Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA. Clinical Rheumatol 2011; 30:1201-1207.
19. Shen H, Goodall JC, Gaston JSH. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum 2009; 60:1647-1656.
20. Niu Q, Cai B, Huang Z-, Shi Y-, Wang L-. Disturbed Th17/Treg balance in patients with rheumatoid arthritis. Rheumatol Int 2012; 32:2731-2736.
21. van Hamburg JP, Asmawidjaja PS, Davelaar N etal. Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production. Arthritis Rheum 2011; 63:73-83.
22. Jandus C, Bioley G, Rivals J-P, Dudler J, Speiser D, Romero P. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum 2008; 58:2307-2317.
23. Yamada H, Nakashima Y, Okazaki K etal. Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67:1299-1304.
24. Arroyo-Villa I, Bautista-Caro M-B, Balsa A etal. Frequency of Th17 CD4+ T cells in early rheumatoid arthritis: a marker of anti-CCP seropositivity. PLoS ONE 2012; 7:e42189.
25. Yue C, You X, Zhao L etal. The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients. Rheumatol Int 2010; 30:1553-1557.
26. Kageyama Y, Kobayashi H, Kato N. Infliximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritis. Mod Rheumatol 2009; 19:657-662.
27. Chen D-Y, Chen Y-M, Chen H-H, Hsieh C-W, Lin C-C, Lan J-L. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-alpha therapy. Arthritis Res Ther 2011; 13:R126.
28. Aerts NE, De Knop KJ, Leysen J etal. Increased IL-17 production by peripheral T helper cells after tumour necrosis factor blockade in rheumatoid arthritis is accompanied by inhibition of migration-associated chemokine receptor expression. Rheumatology 2010; 49:2264-2272.
29. Kokkonen H, Söderström I, Rocklöv J, Hallmans G, Lejon K, Rantapää Dahlqvist S. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum 2010; 62:383-391.
30. González-Álvaro I, Ortiz AM, Alvaro-Gracia J etal. Interleukin 15 levels in serum may predict a severe disease course in patients with early arthritis. PLoS ONE 2011; 6:e29492.
31. Lamana A, Ortiz AM, Alvaro-Gracia J etal. Characterization of serum interleukin-15 in healthy volunteers and patients with early arthritis to assess its potential use as a biomarker. Eur Cytokine Netw 2010; 21:186-194.
32. van Roon JA, Van Roy JL, Duits A, Lafeber FP, Bijlsma JW. Proinflammatory cytokine production and cartilage damage due to rheumatoid synovial T helper-1 activation is inhibited by IL-4. Ann Rheum Dis 1995; 54:836-840.
33. Constantin A, Loubet-Lescoulié P, Lambert N etal. Antiinflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis: evidence of increased interleukin-4 and interleukin-10 gene expression demonstrated in vitro by competitive reverse transcriptase-polymerase chain reaction. Arthritis Rheum 1998; 41:48-57.
34. Kim TS, Kang BY, Lee MH, Choe YK, Hwang SY. Inhibition of interleukin-12 production by auranofin, an anti-rheumatic gold compound, deviates CD4+ T cells fro the Th1 to the Th2 pathway. Br J Pharmacol 2001; 134:571-578.
35. Da Silva JAP, Spector TD. The role of pregnancy in the course and aetiology of rheumatoid arthritis. Clin Rheumatol 1992; 11:189-194.
36. Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today 1993; 14:353-356.
37. Miossec P, Naviliat M, D'Angeac AD, Sany J, Banchereau J. Low levels of interleukin-4 and high levels of transforming growth factor β in rheumatoid synovitis. Arthritis Rheum 1990; 33:1180-1187.
38. Page C, Smale S, Carty S etal. Interferon-gamma inhibits interleukin-1beta-induced matrix metalloproteinase production by synovial fibroblasts and protects articular cartilage in early arthritis. Arthritis Res Ther 2010; 12:R49.
39. Williams AS, Richards PJ, Thomas E etal. Interferon-γ protects against the development of structural damage in experimental arthritis by regulating polymorphonuclear neutrophil influx into diseased joints. Arthritis Rheum 2007; 56:2244-2254.
40. Knudsen L, Klarlund M, Skjødt H etal. Biomarkers of inflammation in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity and radiographic outcome. J Rheumatol 2008; 35:1277-1287.
41. Choy EHS, Smith CM, Farewell V etal. Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann Rheum Dis 2008; 67:656-663.
42. Gottenberg J-E, Dayer J-M, Lukas C etal. Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohort. Ann Rheum Dis 2012; 71:1243-1248.
43. Cascão R, Moura R, Perpétuo I etal. Identification of a cytokine network sustaining neutrophil and Th17 activation in untreated early rheumatoid arthritis. Arthritis Res Ther 2010; 12:R196.